BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 7868954)

  • 1. Epidemiologic characteristics of leprosy reactions.
    Scollard DM; Smith T; Bhoopat L; Theetranont C; Rangdaeng S; Morens DM
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):559-67. PubMed ID: 7868954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
    Becx-Bleumink M; Berhe D
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for erythema nodosum leprosum.
    Manandhar R; LeMaster JW; Roche PW
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
    Pocaterra L; Jain S; Reddy R; Muzaffarullah S; Torres O; Suneetha S; Lockwood DN
    Am J Trop Med Hyg; 2006 May; 74(5):868-79. PubMed ID: 16687695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence and management of leprosy reaction in China in 2005.
    Shen J; Liu M; Zhou M; Wengzhong L
    Lepr Rev; 2009 Jun; 80(2):164-9. PubMed ID: 19743620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological characteristics of leprosy reactions: 15 years experience from north India.
    Kumar B; Dogra S; Kaur I
    Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):125-33. PubMed ID: 15301592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Leprosy in The Netherlands in the period 1970-1991].
    Post E; chin-A-Lien RA; Bouman C; Naafs B; Faber WR
    Ned Tijdschr Geneeskd; 1994 Sep; 138(39):1960-3. PubMed ID: 7935946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current profile of active leprosy in Greece; a five-year retrospective study (1988-1992).
    Kyriakis KP; Kontochristopoulos GJ; Panteleos DN
    Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):547-51. PubMed ID: 7868952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. II. Reactions.
    Schreuder PA
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):159-69. PubMed ID: 9728448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexplained delayed nerve impairment in leprosy after treatment.
    Rosenberg NR; Faber WR; Vermeulen M
    Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India.
    Lockwood DN; Vinayakumar S; Stanley JN; McAdam KP; Colston MJ
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):8-15. PubMed ID: 8326184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased incidence of cytoplasmic ANCA (cANCA) and other autoantibodies in leprosy patients from western India.
    Pradhan V; Badakere SS; Shankar Kumar U
    Lepr Rev; 2004 Mar; 75(1):50-6. PubMed ID: 15072126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.
    Boerrigter G; Pönnighaus JM; Fine PE; Wilson RJ
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):255-61. PubMed ID: 2071983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
    Rea TH; Sieling PA
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study.
    Schreuder PA
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):149-58. PubMed ID: 9728447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
    Vijayakumaran P; Manimozhi N; Jesudasan K
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
    Kumar A; Girdhar A; Girdhar BK
    Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis.
    Santaram V; Porichha D
    Indian J Lepr; 2004; 76(4):310-20. PubMed ID: 16119141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactions in borderline leprosy.
    Ramu G; Desikan KV
    Indian J Lepr; 2002; 74(2):115-28. PubMed ID: 12708730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.